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Abstract This paper presents results of 131I thyroid
activity measurements in 30 members of the nuclear
medicine personnel of the Department of Endocrinology
and Nuclear Medicine Holy Cross Cancer Centre in Kielce,
Poland. A whole-body spectrometer equipped with two
semiconductor gamma radiation detectors served as the
basic research instrument. In ten out of 30 examined staff
members, the determined 131I activity was found to be
above the detection limit (DL = 5 Bq of 131I in the thy-
roid). The measured activities ranged from (5 ± 2) Bq to
(217 ± 56) Bq. The highest activities in thyroids were
detected for technical and cleaning personnel, whereas the
lowest values were recorded for medical doctors. Having
measured the activities, an attempt has been made to esti-
mate the corresponding annual effective doses, which were
found to range from 0.02 to 0.8 mSv. The highest annual
equivalent doses have been found for thyroid, ranging from
0.4 to 15.4 mSv, detected for a cleaner and a technician,
respectively. The maximum estimated effective dose cor-
responds to 32% of the annual background dose in Poland,
and to circa 4% of the annual limit for the effective dose
due to occupational exposure of 20 mSv per year, which is
in compliance with the value recommended by the Inter-
national Commission on Radiological Protection.
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Introduction
Iodine is one of the elements that are essential for proper
functioning of the human organism. In adolescents, the
regular iodine content varies between 30 and 50 mg
(Venturi et al. 2000). The majority of iodine is stored in the
thyroid gland, where an iodine–sodium symporter mecha-
nism regulates iodine accumulation against the electro-
chemical gradient. The specific and natural iodine affinity
of the thyroid proved extremely useful for nuclear medi-
cine. While iodine has as many as 36 known unstable iso-
topes, 131I is the radioisotope most frequently applied in
nuclear medicine. In fact, it was used for the first time in
1942 to treat hyperthyroidism (Seanger et al. 1979). Since
then it has been widely applied both in diagnosis and
treatment of thyroid-related illnesses. 131I is also used in
kidney and bladder function tests.
At present, 42 staff members are employed at the
Department of Endocrinology and Nuclear Medicine Holy
Cross Cancer (E&NM HCC) in Kielce, Poland. The team
consists of 25 nurses, nine medical doctors, two technicians
and six cleaning personnel. 131I is applied by the staff both
in thyroid scintigraphy and in hyperthyroidism and thyroid
cancer treatment. In total, circa 1500 radio-iodine treatment
sessions are performed annually. In general, medical staff
dealing with nuclear medicine should be entirely safe in
their professional environment. Nevertheless, their
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exposure to radioactive iodine seems to be partially
uncontrolled while they perform their duties, namely while
administering iodine in the form of tablets or solutions or
while taking care of the patients already treated with the
isotope. To verify such a hypothesis, 131I activity mea-
surements in the thyroids of the personnel employed at the
Department of E&NM HCC were performed.
Material and method
Medical staff
The present study included 30 employees of the Depart-
ment of E&NM HCC in Kielce, Poland, which corresponds
to circa 70% of all of the staff employed. 131I activities in
two technicians, 19 nurses, three medical doctors and six
cleaning personnel have been measured. The group in the
study consisted of one man and 29 women. The man was
46 years old at the time of measurement, whereas the
women were aged 36–58 years. The research was approved
by the Bioethics Committee at the Regional Medical
Chamber in Krakow.
131I activity measurements
131I thyroid activity measurements in the medical personnel
were performed with the whole-body spectrometer at the
Institute of Nuclear Physics, Polish Academy of Sciences
in Krakow. The dimensions of the shielded spectrometer
chamber are 2 m in length, 1.2 m in width and 1.3 m in
height, and it is shielded both with a 17-cm-thick shield
made of nineteenth-century steel and a 2-cm layer of
electrolytic copper. The total mass of the shielding is 18 t.
The spectrometer consists of two germanium detectors
manufactured by Ortec, each characterised by a relative
efficiency of 30% (Mietelski et al. 2013). Performance
calibration was carried out with an adult thyroid phantom
including a sodium iodide solution with an activity of ca
6 kBq (Kierepko et al. 2014). A phantom thyroid lobe with
dimensions of 5.5 cm in length, 2.5 cm in width and 2 cm
in height was applied. One hundred and fifty activity
measurements were taken to determine the average per-
formance of the detector at various phantom—detector
geometries. Each measurement corresponded to a different
phantom configuration within a 5-cm-wide, 5-cm-long and
3-cm-tall cuboid. The large number of measurements was
necessary because of possible variations of thyroid location
in a healthy human in relation to the detector position. The
average detector efficiency was equal to (0.31 ± 0.08)%.
The measurements were taken over 60 min, with the
detector set perpendicularly to the patient thyroid at a
distance of about 2 cm from the surface of the neck. With
the chosen measurement time, a detection limit of 131I in
the thyroid at the level of 5 Bq was obtained.
Survey research
Each participant in the study was asked to complete a
survey questionnaire. The questions can be divided into
four categories. General questions such as gender and age
formed the first ‘demographic’ category. The second cat-
egory dealt with determining the nature of work with
radioactive iodine including details on the type of tasks and
131I handling, duration of exposure to 131I and contacts
with patients after treatment or diagnostics. The third cat-
egory was concerned with dietary habits, whereas the
fourth category addressed health conditions related to
possible thyroid diseases. The responses provided by the
medical personnel served to support interpretation of the
131I activity measured in the thyroid.
Dose estimation
On the basis of the results obtained for 131I thyroid activity in the
medical personnel, doses were estimated. The initial step was to
determine the nature of the staff exposure. The exposure to 131I
for Department of E&NM HCC employees shows a rather
regular pattern. As for iodine, the effective half-life within a
human body is approximately equal to 7 days (Kalinyak and
McDougall 2003), which is relatively long in comparison with
the occupational procedures that the employees perform. Thus,
the thyroids of the subjects under examination should be ‘ra-
dioactively balanced’. Therefore, the iodine activities measured
in the thyroids of employees were stable.
The next step to estimate the doses was to determine the
professional routines for the medical staff under examination.
Their routine schemes combined with the survey data have
shown that the nurses in the therapeutic part of the department
work one 12-h shift every 3 days. Therapeutic doses are
administered to patients weekly on Fridays. In contrast, the
cleaning staff cleans the rooms of the patients undergoing the
treatment on a regular weekly basis, on Wednesdays.
Subsequently, for employees with 131I detected in their
thyroids, the total iodine absorption in their respiratory
system, and in other organs alike, was reconstructed. A
weekly frequency of iodine intake was assumed for the
cleaning and technical personnel, while for nurses a 3-day
frequency was assumed. The iodine biokinetic model
applied was that developed by Leggett (2010), combined
with the Human Respiratory Tract Model (ICRP 1994;
2002) and Gastro-Intestinal Tract Model (ICRP 1979)
developed by the International Commission on Radiologi-
cal Protection (ICRP). The overall scheme for the model is
shown in Fig. 1, whereas the biological transfer coeffi-
cients are presented in Table 1. SAAM II software by the
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Epsilon Group was applied for the biokinetic modelling
(Barrett et al. 1998).
It was further assumed that the medical staff’s major
exposure was due to iodine in the gaseous fraction (Mietelski
et al. 2005). Elemental and organic iodine gas fractions are
absorbed in the respiratory track in various proportions.
However, whenever it is not possible to distinguish between
elemental and organic iodine, it is recommended by ICRP to
adopt a deposition rate for the elemental iodine. Therefore,
for the present study 100% deposition in the respiratory tract
was assumed, with the respective distribution of 10% in ET1
(anterior nose), 40% in ET2 (posterior nasal passage, larynx,
pharynx and mouth) and 50% in BB (bronchial region)
compartments (ICRP 1995).
Based on the measured 131I activity in the thyroid and
the applied biokinetic models, effective annual doses as
well as equivalent doses for particular organs were calcu-
lated: equivalent doses were calculated as based on the
time-integrated 131I activity and radiation-weighted Sw
factors. In practice, the time-integrated 131I activity was
obtained from computer modelling and the radiation-
weighted Sw factor was calculated with the SEECAL pro-
gram (Oak Ridge National Laboratory, Oak Ridge, TN,
USA), separately for adult men and women.
Results and discussion
131I activity measurements
A total of 30 staff members in the Department of E&NM HCC
in Kielce, Poland, were examined. 131I activity in thyroids was
found to be below the detection limit (DL = 5 Bq of 131I in
the thyroid) for 20 subjects in the study. Among the remaining
10 individuals, 131I thyroid activity ranged from (5 ± 2) to
(217 ± 56) Bq for cleaning staff members and radiology
technicians, respectively. For detailed results, see Table 2.
The uncertainty of the presented results is about one sigma.
131I was detectable in the thyroid of all of the radiology
technicians, half of the cleaning staff members and one-fourth
of the nurses under examination, whereas it remained unde-
tected for all medical doctors.
This distribution pattern can be explained by the types
of duties performed with respect to exposure to 131I: radi-
ology technicians and radiopharmacists were found to be
the most exposed contaminated individuals, because they
directly participate in preparing and administering radio-
pharmaceuticals, where their presence at every treatment
session is required. In contrast, the main duty of medical
doctors is to collect medical surveys, order medical tests
and provide advisory services, so their contact with 131I is
limited. The least consistent results were obtained for the
group of the cleaning staff and nurses. The Department of
E&NM HCC in Kielce is divided into two parts, namely
the diagnostic part and the therapeutic part. Relatively low
activities are administered by the diagnostic division, and
patients are not subjected to a strict isolation regime. This
is different in the therapeutic division, where applied 131I
activities tend to be relatively high and patients are com-
pletely isolated. It is noted that those nurses and cleaning
staff members for whom 131I was detected had worked in
the therapeutic division for over 1 month preceding the
measurements.
Modelling
The next stage of the study was to estimate doses for the
medical staff members. The 131I total absorption into the
Fig. 1 General biokinetic model applied in the present study. The
model combines ICRP Human Respiratory Track Model, Gastro-
Intestinal Tract Model and Leggett systemic model (ET1
extrathoracic region, ET2 posterior nasal passages, LN ET, TH
lymph nodes, BB bronchial, bb bronchiolar, AI alveolar–interstitial)
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respiratory system and 131I activity in the remaining organs
were reconstructed by computer modelling, to match the
measured 131I thyroid activity. The reconstructed results
along with the parameters assumed for the dose calcula-
tions are presented in Table 3. A strong correlation was
found between the simulated and measured thyroid activ-
ities (Pearson’s R2 = 0.996, p = 0.000), although the
simulated activities were significantly higher than the
measured activities (Student’s t test for paired samples:
p = 0.029).le 5
Based on the computer modelling data, the time-inte-
grated 131I activity in the source organs was also calculated
(Table 4).
Dose estimation
The estimated effective annual dose received by the med-
ical staff in the study was found to vary between 0.02 and
0.8 mSv per year. Not surprisingly, the highest annual
equivalent organ doses were found for the thyroid, ranging
from 0.4 to 15.4 mSv, as obtained for a cleaner and a
technician, respectively (Table 5).
While using radiopharmaceuticals for therapeutic or
diagnostic purposes in medicine, appropriate radiological
safety rules should be observed and proper safety measures
taken. Exposure risk assessment methodologies to be applied
to medical staff usually take into account only the external
exposure to radiation, and as such are based either on readings
from individual thermoluminescent dosimeters or on mea-
surements performed either with scintillation probes or Geiger
counters (Chiesa et al. 1997; Lancelot et al. 2008). Doses
estimated in that way determine the exposure of medical staff
dealing with 131I, 99mTc, 18F, 90Y and 153Sm isotopes. Effec-
tive doses for medical staff determined for most of the singular
medical procedures varied within the range (0.2–0.4) lSv per
treatment. While administering treatment units of 131I-lipi-
odol, the annual dose for hands and chest of medical staff
varied within the range from 140 to 443 lSv and from 12 to
23 lSv (Garin et al. 2003), respectively, whereas in another
study the annual doses for hands and whole body were 165 and
3.8 lSv (Lancelot et al. 2008), respectively.
The methodology applied in the present study of mea-
suring internal exposure is rarely applied. Similar studies
have also been carried out at three hospitals in Warsaw
(Poland). The reported levels of activities and doses were
similar to those presented here, typically falling for effec-
tive dose within the range from 0.21 to 1.44 mSv per year
(Krajewska and Pachocki 2013).
It is emphasised that such doses do not exceed the doses
set out in the 2013/59 Euroatom (2014) directive, where
the limit of the effective dose for occupational exposure is
20 mSv per year. However, under special circumstances, or
for certain exposure situations specified in the national
legislation, a higher effective dose, specifically up to
50 mSv, may be authorised by a competent authority for a
certain year, provided that the average annual dose over
five consecutive years, including the year(s) for which the
limit has been exceeded, does not exceed 20 mSv. The
Table 1 Parameter values of the Leggett 131I systemic model (Leg-
gett 2010)
Pathway Transfer coefficient (day-1)
Blood 1 to thyroid 1 7.26
Blood 1 to urinary bladder contents 11.84
Blood 1 to salivary glands 5.16
Blood 1 to stomach wall 8.60
Blood 1 to other 1 600
Blood 1 to kidneys 1 25
Blood 1 to liver 1 15
Salivary glands to stomach contents 50
Stomach wall to stomach contents 50
Thyroid 1 to thyroid 2 95
Thyroid 1 to blood 1 36
Thyroid 2 to blood 2 0.0077
Thyroid 2 to blood 1 0
Other 1 to blood 1 330
Other 1 to other 2 35
Other 2 to other 1 56
Kidney 1 to blood 1 100
Liver 1 to blood 1 100
Blood 2 to other 3 15
Other 3 to blood 2 21
Other 3 to other 4 1.2
Other 4 to other 3 0.62
Other 4 to blood 1 0.14
Blood 2 to kidneys 2 3.6
Kidneys 2 to blood 2 21
Kidneys 2 to blood 1 0.14
Blood 2 to liver 2 21
Liver 2 to blood 2 21
Liver 2 to blood 1 0.14
Stomach contents to SI contents 20.57
SI contents to blood 1 594
Urinary bladder contents to urine 12
22 Radiat Environ Biophys (2017) 56:19–26
123
Table 2 Measured 131I thyroid
activity
Subject code Gender Age Profession 131I Thyroid activity [Bq]
T1 M 46 Technician 217 ± 56
T2 F 53 Technician 107 ± 28
C1 F 40 Cleaner 152 ± 40
C2 F 46 Cleaner 91 ± 24
C3 F 42 Cleaner 5 ± 2
C4 F 55 Cleaner \5
C5 F 40 Cleaner \5
C6 F 58 Cleaner \4
N1 F 39 Nurse 66 ± 17
N2 F 44 Nurse 38 ± 10
N3 F 37 Nurse 38 ± 10
N4 F 46 Nurse 16 ± 5
N5 F 51 Nurse 15 ± 4
N6 F 40 Nurse \5
N7 F 50 Nurse \5
N8 F 46 Nurse \6
N9 F 43 Nurse \4
N10 F 41 Nurse \5
N11 F 36 Nurse \5
N12 F 50 Nurse \5
N13 F 43 Nurse \5
N14 F 49 Nurse \5
N15 F 53 Nurse \5
N16 F 38 Nurse \5
N17 F 40 Nurse \5
N18 F 45 Nurse \5
N19 F 45 Nurse \5
D1 F 44 Medical doctor \5
D2 F 49 Medical doctor \5
D3 F 52 Medical doctor \5













T1 M 750 Once a week 50 230 217 ± 56
T2 F 400 Once a week 50 120 107 ± 28
C1 F 500 Once a week 50 150 152 ± 40
C2 F 350 Once a week 50 100 91 ± 24
C3 F 15 Once a week 50 5 5 ± 2
N1 F 80 Every 3 days 112 70 66 ± 17
N2 F 50 Every 3 days 112 40 38 ± 10
N3 F 50 Every 3 days 112 40 38 ± 10
N4 F 20 Every 3 days 112 17 16 ± 5
N5 F 20 Every 3 days 112 17 15 ± 4
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same limits for occupational exposure are recommended by
ICRP (2007) and required by Polish law.
Conclusions
The maximum effective dose estimated in the present study
for medical staff handling with 131I corresponds to 32% of
the mean annual background effective dose due to natural
sources in Poland, i.e. 2.48 mSv per year (Janik and
Tokonami 2009). Moreover, the maximum estimated
effective dose found here for medical staff was signifi-
cantly below the annual limit set for occupational expo-
sure, compliant with the value of 20 mSv recommended by
ICRP (2007). Consequently, any negative health impact
due to such doses is unlikely for the medical staff under
examination. Nevertheless, the dose equivalent values
estimated in the present study for the thyroid provide a
worrying picture, because the dose equivalents determined
for the cleaning staff members and the radiopharmaceutical
technician were equal to 0.4 and 15.4 mSv, respectively.
Currently, at Polish nuclear medicine units only the staff
exposure to external radiation is monitored. Measurements
by thermoluminescent dosimeters, however, will not pro-
vide any information on the doses due to radio-iodine
incorporated into the body. Therefore, the radiological
safety standards applied at present fail to meet the
requirements of the so-called conservative assessment rule,
where upper dose limits should be estimated. With internal
dose estimation for the incorporated radio-iodine entirely
ignored, the assessed doses tend to be underestimated, and
the doses due to the radionuclides absorbed into the body
remain undetermined. Therefore, periodic and systematic
monitoring of the internal contamination should be inte-
grated into radiological protection standards for teams
dealing with highly radioactive 131I.













N4, N5 (15 Bq,
16 Bq)
Thyroid 9.41 9 109 5.02 9 109 6.28 9 109 4.39 9 109 1.88 9 108 2.24 9 109 1.40 9 109 5.61 9 108
UBC 1.66 9 108 8.84 9 107 1.11 9 108 7.74 9 107 3.32 9 106 3.92 9 107 2.45 9 107 9.80 9 106
Kidneys 5.95 9 107 3.17 9 107 3.96 9 107 2.77 9 107 1.19 9 106 1.41 9 107 8.82 9 106 3.53 9 106
Blood 2.70 9 108 1.44 9 108 1.80 9 108 1.26 9 108 5.41 9 106 6.42 9 107 4.01 9 107 1.61 9 107
Liver 1.25 9 108 6.66 9 107 8.33 9 107 5.83 9 107 2.50 9 106 2.99 9 107 1.87 9 107 7.47 9 106
Other 6.71 9 108 3.58 9 108 4.47 9 108 3.13 9 108 1.34 9 107 1.59 9 108 9.94 9 107 3.98 9 107
Salivary glands 1.74 9 107 9.30 9 106 1.16 9 107 8.14 9 106 3.49 9 105 4.12 9 106 2.58 9 106 1.03 9 106
St contents 1.48 9 108 7.90 9 107 9.88 9 107 6.91 9 107 2.96 9 106 3.50 9 107 2.19 9 107 8.76 9 106
St wall 2.91 9 107 1.55 9 107 1.94 9 107 1.36 9 107 5.81 9 105 6.87 9 106 4.29 9 106 1.72 9 106
SI 5.08 9 106 2.71 9 106 3.39 9 106 2.37 9 106 1.02 9 105 1.20 9 106 7.50 9 105 3.00 9 105
ULI 2.04 9 107 1.09 9 107 1.36 9 107 9.51 9 106 4.08 9 105 4.83 9 106 3.02 9 106 1.21 9 106
LLI 3.38 9 107 1.80 9 107 2.25 9 107 1.58 9 107 6.75 9 105 8.01 9 106 5.00 9 106 2.00 9 106
ET1 3.04 9 108 1.62 9 108 2.03 9 108 1.42 9 108 6.09 9 106 7.19 9 107 4.50 9 107 1.80 9 107
ET2 7.36 9 106 3.92 9 106 4.90 9 106 3.43 9 106 1.47 9 105 1.74 9 106 1.09 9 106 4.35 9 105
BB 1.50 9 107 8.01 9 106 1.00 9 107 7.00 9 106 3.00 9 105 3.55 9 106 2.22 9 106 8.87 9 105
UBC urinary bladder contents, St stomach, SI small intestine, ULI upper large intestine, LLI lower large intestine, ET1 anterior nose, ET2
posterior nasal passage, larynx, pharynx and mouth, BB the bronchial region
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